anacetrapib: Clinical Trials

6 completed, 1 active not recruiting, 1 terminated. 8 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	8	Completed 6, Active not recruiting 1, Terminated 1

Follow anacetrapib: new trials by email Literature Review of anacetrapib trials Research Report on anacetrapib

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) Anacetrapib, Placebo - Hyperlipoproteinemia Type II, Homozygous Familial Hypercholesterolemia	Phase 3	Terminated	Merck Sharp & Dohme LLC	2	2013-06-01	2015-06-01
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022) Anacetrapib, Placebo - Hypercholesterolemia	Phase 3	Completed	Merck Sharp & Dohme LLC	589	2013-05-13	2020-05-29
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) Anacetrapib, Placebo for anacetrapib - Heterozygous Familial Hypercholesterolemia (HeFH)	Phase 3	Completed	Merck Sharp & Dohme LLC	68	2013-05-01	2016-04-25
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1) Anacetrapib, Placebo for anacetrapib - Dyslipidemia	Phase 3	Completed	Merck Sharp & Dohme LLC	307	2013-03-14	2017-06-01
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021) Anacetrapib 100 mg, Placebo for anacetrapib 100 mg, Anacetrapib 25 mg - Hypercholesterolemia	Phase 3	Completed	Merck Sharp & Dohme LLC	459	2012-11-06	2017-04-17
Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) Anacetrapib, Placebo - Hyperlipoproteinemia Type II, Hypercholesterolemia, Familial	Phase 3	Completed	Merck Sharp & Dohme LLC	306	2012-02-03	2019-10-14
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification Anacetrapib, Placebo anacetrapib - Atherosclerotic Cardiovascular Disease	Phase 3	Active not recruiting	University of Oxford	30449	2011-06-01	2024-06-25
Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) anacetrapib, Comparator: placebo - Coronary Heart Disease (CHD), CHD Risk-Equivalent Disease	Phase 3	Completed	Merck Sharp & Dohme LLC	1623	2008-03-24	2017-12-11

Conditions studied

Hypercholesterolemia (2)  ·  Hyperlipoproteinemia Type II (2)  ·  Atherosclerosis (1)  ·  Coronary Disease (1)  ·  Dyslipidemias (1)  ·  Homozygous Familial Hypercholesterolemia (1)  ·  Inhibition, Psychological (1)  ·  Vascular Diseases (1)

Sponsors

Merck Sharp & Dohme LLC (7)  ·  University of Oxford (1)

Countries

United Kingdom (1)

Top investigators

Louise Bowman (1)  ·  Martin Landray (1)

Results publications

PMID 19781408, PMID 21082868, PMID 22180633, PMID 22696435, PMID 24737712, PMID 25670362, PMID 27131642, PMID 27956003, PMID 28478132, PMID 28624096, PMID 28847206, PMID 31331193, PMID 34910136, PMID 37750555, PMID 41843779